Skip to main content

Translating disease to cardiovascular health

Objective

Cardiovascular disease (CVD) is the leading cause of death in Europe and the world. Drugs that lower cholesterol in blood are the most efficient drugs used to date but we are currently still facing a 50-70% residual risk of suffering from CVD. This clearly illustrates an urgent need for the identification, characterization and validation of novel therapeutically relevant targets. Over the last decade, numerous targets have emerged but not led to successful treatment of patients. In addition to missing opportunities of health improvement beyond statins, the 92% failure rate of novel drugs also puts a large burden on the EU economy.
While the causal relation between levels of lipids in plasma and CVD forms the basis of this proposal, the challenge taken up by TransCard is ‘Translating disease into Cardiovascular health’: It means that insight into the molecular origin of disturbed lipid metabolism in patients as well as the identification of lipoprotein phenotypes with causal relationships to atherosclerosis can provide immediate targets for pharmaceutical intervention leading to successful treatment of this disease.
TransCard will prioritize existing and emerging targets and embark on novel unbiased approaches to identify and prioritize novel key regulators of lipid and lipoprotein metabolism. Achieving this aim will be ensured by a multidisciplinary research consortium of two SMEs and four academic partners who use innovative biotechnological and bioinformatics tools and have direct access to unique biobanks and large-scale population cohorts. This team will also help to translate the basic insight into biology into clinical use by subjecting promising targets from top level basic research to validation of their CVD association in large prospective and patient cohorts. Targets passing these tests will be studied in mice to shed further light on the feasibility of pharmaceutical intervention thereby providing lead targets for further development by other parties.

Field of science

  • /natural sciences/biological sciences/biochemistry/biomolecules/lipids
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ACADEMISCH ZIEKENHUIS GRONINGEN
Address
Hanzeplein 1
9713 GZ Groningen
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 554 408
Administrative Contact
Johanna M. Van Apeldoorn (Ms.)

Participants (7)

ENTELECHON GMBH

Participation ended

Germany
Address
St. Veit-weg 2
93051 Regensburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Werner Deininger (Dr.)
POLYQUANT GMBH
Germany
EU contribution
€ 703 153
Address
Industriestrasse 1
93077 Bad Abbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Werner Deininger (Dr.)
NEBION AG
Switzerland
EU contribution
€ 1 108 900
Address
Hohlstrasse 515
8048 Zurich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Philip Zimmermann (Dr.)
REGION HOVEDSTADEN
Denmark
EU contribution
€ 771 500
Address
Kongens Vaenge 2
3400 Hillerod
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Christine Nuding (Ms.)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 765 800
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Barry Van Rookhuizen (Dr.)
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 871 000
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Arnold Von Eckardstein (Prof.)
ACIES Consulting Group SAS
France
EU contribution
€ 109 882
Address
Rue De La République 69
69002 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Marie-Laure Muiras (Dr.)